Alterity Therapeutics (ATHE) Interest & Investment Income (2018 - 2019)
Alterity Therapeutics (ATHE) posted quarterly Interest & Investment Income of $9655.5 for Q4 2019, down 79.72% year-over-year from $47609.3 in Q4 2018, and down 79.72% quarter-over-quarter from $47609.3 in Q4 2018.
Alterity Therapeutics (ATHE) Interest & Investment Income (2018 - 2019) Analysis & Trends
Alterity Therapeutics' Interest & Investment Income history runs 2 years deep, the most recent figure standing at $9655.5 for Q4 2019.
- In Q4 2019, Interest & Investment Income fell 79.72% year-over-year to $9655.5; the TTM figure through Dec 2019 stood at $465970.4 (changed N/A YoY), while the FY2025 annual figure was $285819.6, up 61.58% from the prior year.
- Interest & Investment Income for Q4 2019 stood at $9655.5, down from $47609.3 in the prior quarter.
- The five-year high for Interest & Investment Income was $47609.3 in Q4 2018, with the low at $9655.5 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 9,655.51 |
| Dec 31, 2018 | 47,609.30 |